期刊
EUROPEAN JOURNAL OF IMMUNOLOGY
卷 45, 期 12, 页码 3257-3268出版社
WILEY
DOI: 10.1002/eji.201445243
关键词
Antigen processing; Cellular cytotoxicity; ER-aminopeptidase; Melanoma; Melanoma antigen recognized by T cells/melanoma antigen A; PA28; Proteasome subunit
类别
资金
- Deutsche Forschungsgemeinschaft [SFB-TR36, CRC854]
- Deutsche Krebshilfe [106861]
- Berliner Krebsgesellschaft e.V. [Z:SEFF200907]
- CRG grant of the Berlin Institute of Health (BIH)
- NRW/EU-Ziel2-Programm [005-1006-0057]
The immunodominant MART-1(26(27)-35) epitope, liberated from the differentiation antigen melanoma antigen recognized by T cells/melanoma antigen A (MART-1/Melan-A), has been frequently targeted in melanoma immunotherapy, but with limited clinical success. Previous studies suggested that this is in part due to an insufficient peptide supply and epitope presentation, since proteasomes containing the immunosubunits beta 5i/LMP7 (LMP, low molecular weight protein) or beta 1i/LMP2 and beta 5i/LMP7 interfere with MART-1(26-35) epitope generation in tumor cells. Here, we demonstrate that in addition the IFN-gamma-inducible proteasome subunit beta 2i/MECL-1 (multicatalytic endopeptidase complex-like 1), proteasome activator 28 (PA28), and ER-resident aminopeptidase 1 (ERAP1) impair MART-1(26-35) epitope generation. beta 2i/MECL-1 and PA28 negatively affect C-and N-terminal cleavage and therefore epitope liberation from the proteasome, whereas ERAP1 destroys the MART1(26-35) epitope by overtrimming activity. Constitutive expression of PA28 and ERAP1 in melanoma cells indicate that both interfere with MART-1(26-35) epitope generation even in the absence of IFN-gamma. In summary, our results provide first evidence that activities of different antigen-processing components contribute to an inefficient MART-1(26-35) epitope presentation, suggesting the tumor cell's proteolytic machinery might have an important impact on the outcome of epitope-specific immunotherapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据